Optiscan Pockets $1.69M Government R&D Refund to Fund Commercialisation Push
Optiscan locks in $1.69M R&D tax refund to fuel continued innovation
Optiscan Imaging (ASX: OIL) has received its FY25 research and development tax refund of $1,693,714 under the Australian Federal Government’s R&D Tax Incentive program. The refund is in line with company expectations and reflects continued qualifying R&D activity, directly supporting investment in clinical programs and the commercialisation of Optiscan’s confocal laser endomicroscopy technology.
When big ASX news breaks, our subscribers know first
What the R&D tax incentive means for Optiscan investors
Understanding the Australian R&D Tax Incentive program
The Australian Government’s R&D Tax Incentive is a federal program that provides eligible companies undertaking qualifying R&D activities with a refundable tax offset of up to 43.5%. Unlike a standard tax deduction, which only reduces taxable income, a refundable tax offset returns cash to the company regardless of whether it is profitable.
For investors, the distinction matters. This type of refund represents non-dilutive funding: recurring, government-backed cash that extends a company’s runway without requiring the issuance of new equity. For clinical-stage and commercialisation-phase companies like Optiscan, it can be a meaningful source of operating capital.
Why Optiscan’s FY25 refund remains elevated
Both the FY24 and FY25 refunds remain elevated relative to prior years, a direct result of the Advance and Overseas Finding application secured in FY24. This finding enables eligible overseas R&D expenditure to be claimed under the Australian Government’s R&D Tax Incentive program, broadening the scope of qualifying costs.
| Financial Year | R&D Refund Received | Key Driver |
|---|---|---|
| FY24 | $1,775,733 | Advance and Overseas Finding application secured |
| FY25 | $1,693,714 | Continued eligible overseas R&D expenditure under Advance and Overseas Finding |
The year-on-year figures signal sustained R&D investment levels, with the modest reduction between FY24 and FY25 consistent with normal variation in qualifying expenditure rather than any material change in program participation.
Strengthening the funding base as commercialisation advances
The FY25 refund represents a meaningful contribution to Optiscan’s non-dilutive funding position at a critical phase of commercialisation activity. The company has stated its intention to direct funds toward key R&D programs and clinical studies, consistent with the strategic focus outlined in the announcement.
For investors, recurring and predictable government-backed cash inflows of this nature reduce reliance on capital markets during the commercialisation phase, a factor worth noting as the company progresses toward broader market adoption of its technology.
Dr Camile Farah, CEO and Managing Director
“The Australian Government’s R&D tax incentive continues to provide valuable support for Optiscan’s innovation pipeline and clinical development activities. This FY25 refund reinforces our funding position and supports continued investment in key R&D programs and clinical studies as we progress toward broader commercialisation of our technology. We welcome the ongoing support of initiatives that help Australian innovators translate globally relevant medical technologies into meaningful clinical and shareholder value.”
The next major ASX story will hit our subscribers first
About Optiscan and the road ahead
Optiscan Imaging Ltd (ASX: OIL) is a commercial-stage medical technology company specialising in confocal laser endomicroscopy, enabling live optical biopsy at the single-cell level. Its addressable market spans digital pathology, precision surgery, and the fast-growing digital health market, including robotic surgery.
Continued R&D investment, supported by refunds like this, positions Optiscan to progress toward broader commercialisation of its technology suite. Key differentiators underpinning that outlook include:
- Spatial resolution more than 1,000x that of medical CT and MRI
- A patented “tissue contact” method enabling non-destructive, 3D, in-vivo imaging
- An expanding product suite targeting surgery, pathology, and robotic surgery markets
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already ahead of the market and never miss a move. Click the “Free Alerts” button at StockWire X to get started today.